Figure 2

Standard nomenclature for mAbs identifies their source with the last 4 or 5 letters: -omab, murine: -ximab, chimeric: -zumab, humanized: and -umab, human. The middle part of the name reflects the disease indication for which the mAb was initially intended: -lim for immune and inflammatory diseases, -cir for cardiovascular disorders, and -tu for tumors or neoplastic conditions. The first 3 or 4 letters may be chosen by the sponsor. Modified (by adding the structure of a bispecific antibody) from reference 28, with permission.